A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SUNRISE
- 17 Mar 2017 Planned End Date changed from 27 Jul 2016 to 1 Dec 2017.
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology. (n = 20)
- 07 Feb 2014 New source identified and integrated, ClincialTrials.gov record (NCT02058901).